SEC Form 4 · accession 0001178913-18-001594
Foamix Pharmaceuticals Ltd. · FOMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Aharon Schwartz
Director
Period of report
May 8, 2018
Accepted (ET)
May 10, 2018 · 5:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001606645
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OptionsF1,F2 | $5.02 | May 8, 2018 | A | 24,883 | A | — | May 8, 2028 | Ordinary Shares | 24,883 | 24,883 | D |
Explanation of responses
- F1Each option represents a contingent right to purchase one ordinary share of the issuer.
- F2The ordinary shares underlying these options vest over a 12 month period, in equal, quarterly installments, ending May 8, 2019.